

# 24 **Summary**





#### 70 **Introduction**

71 Human immunodeficiency virus type I (HIV-1) is a retrovirus that infects immune cells  $72$  by binding to receptors on the cell surface<sup>1</sup>. HIV-1 infects host cells by integrating a copy of the 73 viral genome into the host genome, resulting in proviruses that then hijack the host cell's  $74$  replicative machinery to produce the building blocks of infectious particles<sup>1</sup>. The HIV-1 lifecycle 75 may rapidly deplete host CD4+ T cell populations and disrupt global immune dynamics<sup>2</sup>. 76 Disruptions to the host immune system predispose people living with HIV-1 (PLWH) to life- $177$  threatening comorbidities<sup>3</sup>. Since 1996, life expectancy and quality of life for PLWH have risen 78 due to the advent of antiretroviral therapies (ARTs) that pharmacologically inhibit key processes  $79$  of the retroviral life cycle<sup>4</sup>. Unfortunately, ART merely suppresses retroviral processes, 80 emphasizing the need for cure strategies that rid individuals of latent proviral reservoirs which 81 may resume infectious particle formation after a lapse in treamtent<sup>5,6</sup>. One such reservoir site is 82 the gastrointestinal (GI) associated lymphoid tissue  $(GALT)^{7,8}$ , which is particularly rich in  $83$   $CD4+ T$  cells<sup>9</sup>. HIV-1 induced immunopathologies in the GALT are associated with severe 84 comorbidities in  $PLWH^{10,11}$ . Many of these pathologies could be sustained by the accumulation 85 of plasmacytoid dendritic cells (pDCs) that are trafficked to the GI tract during chronic HIV-1  $86$  infection<sup>12</sup>. Models of Simian Immunodeficiency Virus (SIV), a retrovirus closely related to 87 HIV-1, demonstrate that pDCs traffic from the circulation, where they are depleted, to the GALT, 88 where their overabundance contributes to immunopathologies that allow the site to become the 89 . primary source of viral replication<sup>13,14</sup>. pDCs reflect a unique subset of DCs whose primary 90 function is not antigen presentation but is instead immunomodulation through the release of 91 . cytokines<sup>15</sup>. In the acute stages of HIV-1 infection, pDCs produce type 1 interferons (IFN-Is) as 92 one of the first lines of defense against the virus<sup>16</sup>, and are therefore protective. However, the



115 components of human pathologies, we hypothesize that their consideration would identify novel 116 markers of HIV-1 pathogenesis in the gut.



- 138 "--outSAMstrandField intronMotif --outFilterMultimapNmax 200 --winAnchorMultimapNmax
- 200" for the purpose of capturing multimapping ERE reads. We then used Telescope (v1.0.3)<sup>49</sup>,
- 140 which utilizes an expectation-maximization algorithm to improve upon the definition of
- 141 ubiquitously mapping ERE transcripts to a custom annotation, for locus-specific approximation
- 142 of ERE expression. The Telescope assign module was performed using the parameters "--
- 143 theta\_prior 200000 -- max\_iter 1000" to align reads to a custom annotation of EREs accessible at
- 144 https://github.com/mlbendall/telescope\_annotation\_db. Metadata for the ERE annotation
- 145 predicting the intronic, exonic, and intergenic status of individual loci in the Telescope
- 146 annotation relative to coding gene annotations can be found at
- 147 https://github.com/liniguez/Telescope\_MetaAnnotations. Original code produced for analysis
- 148 can be accessed at https://github.com/NicholasDopkins/JuneHIVMucosa.
- 149
- 150 *Differential expression analysis*

151 Lowly abundant EREs were filtered from downstream analysis by ensuring that all EREs 152 possessed at least 2 reads within 10% of the total samples. Differential expression analysis was 153 performed between the ERE expression profiles of uninfected control and PLWH colon biopsies 154 using standard DESEQ2 (v1.30.1)<sup>50</sup> parameters. Differential expression analysis was performed 155 between the ERE expression profiles of IFN-I stimulated gut CD4+ T cells using DESEQ2 with 156 the parameters "parallel =  $T$ " and "betaPrior =  $T$ ". Results were extracted as DESEQ objects, 157 with a numbered contrast of each group compared against all others. Differentially expressed 158 EREs were visualized with the packages pheatmap (v1.0.12), ggVennDiagram (v1.2.2)<sup>51</sup> and 159 EnhancedVolcano (v1.8.0). Individual EREs were visualized with a custom function that 160 overlays geom jitter and geom boxplot functions provided by ggplot2 v(3.3.5)<sup>52</sup> to produce a



184 when stated. For significance of post hoc tests the following scale is used to indicate p values

185 when applicable: ns,  $p > 0.05$ ; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.005$ 

186

187 *Clinical cohort* 

188 ERE expression analyses were conducted using FASTQ files from previously generated RNAseq 189 data collected from colonic tissue and PBMC fractions collected from 19 PLWH and 13 age- and 190 sex-matched controls, and associations with features of HIV-1 pathogenesis were determined 191 using archived datasets of colon and systemic immunological and virological parameters<sup>17,18,53,54</sup>. 192 On average, PLWH had been infected with HIV-1 (defined by the first HIV-1 seropositive test) 193 for 5.25±1.1 (mean±SEM) years. PLWH were ART-naive or were not on ART for more than 7 194 days in the preceding 6 months, and had CD4 T cell counts >200 cells/μl within 3 months of 195 clinical visit. Exclusion criteria for both cohorts are extensively detailed elsewhere<sup>53</sup>. In addition 196 to blood samples, study participants underwent a flexible sigmoidoscopy with multiple colon 197 pinch biopsies obtained. Clinical characteristics for the study participants included in this current 198 study are detailed in Supplemental Table 1.

199

200 *Immune system characterization of PLWH and uninfected controls* 

201 Methods used to generate the archived datasets have been extensively detailed<sup>17,18,53,54,59,60</sup>. In 202 brief, indicators of systemic inflammation were assessed with plasma IL-6 concentrations by 203 ELISA, and microbial translocation was measured by plasma LPS concentrations with the 204 Limulus Amebocyte Lysate assay<sup>53</sup>. Frequencies of colon mDCs, pDCs, and T cells were 205 determined using multi-color flow cytometry<sup>53,54</sup> and expressed as an absolute number per gram 206 of tissue based on the frequency within viable CD45+ cells, initial cell counts, and biopsy



230 displays discrete changes in the gut microenvironment in viremic individuals prior to the 231 initiation of ART. Further consideration of the phylogenies and chromosomal origin of ERE 232 expression profiles demonstrated no distinctive alterations in PLWH when compared to controls, 233 suggesting no large-scale changes in ERE expression in the gut microenvironment of PLWH 234 (Fig. S1). To infer mechanisms by which HIV-1 infection induces the differential expression of 235 EREs in the gut, we next quantified changes in expression resulting from IFN-I stimulation of 236 uninfected gut-derived CD4+ T cells. IFN-Is do not shift the global landscape of ERE activity at 237 the RNA level (Fig. S2). Discrete changes in locus-specific expression demonstrate that IFN-I 238 activation of uninfected gut CD4+ T cells share upregulated expression of 23 EREs, suggesting 239 that they are IFN-inducible (Fig. S3 and Fig. S4). 7 of these 23 EREs were upregulated in the gut 240 of PLWH, suggesting immune-dependent mechanisms for their in HIV-1 infection, while 35 of 241 the 42 upregulated EREs in PLWH showed no significant induction by IFN-I stimulation (Fig. 242 S5). Collectively, HIV-1 infection upregulates specific EREs in the gut of PLWH through both 243 IFN-dependent and IFN-independent mechanisms.

244

245 *Correlation between gut endogenous retroelement expression and viral load in people living*  246 *with HIV-1* 

247 Pearson's correlation coefficients were calculated for all differentially expressed EREs in 248 the gut of PLWH to identify any potential links with their expression and HIV-1 infection 249 severity as determined by circulating HIV-1 viral load. Of the 59 differentially expressed EREs, 250 three showed near significant (p<0.10) positive correlations between colonic expression and viral 251 load in PLWH. L1FLnI\_1q23.1s possessed a positive association with viral load in the 252 circulation (Fig. 2a) and is upregulated in the colon of PLWH when compared to uninfected

253 controls (Fig. 2b). In PBMCs collected from the same participants, expression of







310

#### 311 **Discussion**

312 In this study, we leverage modulations in ERE activity at the RNA level in the GI tract of 313 untreated PLWH with frequencies of immune cell populations that are likely critical players in  $314$  driving HIV-1 gut pathogenesis<sup>11</sup>. As the derepression of EREs may possess immunomodulatory 315 roles in human diseases  $42,61$ , our results suggest further investigation into their activity in HIV-1 316 pathogenesis. By analysis of RNA sequencing from colon biopsies of uninfected controls vs 317 untreated PLWH, we identified 59 differentially expressed EREs associated with HIV. By 318 finding correlations between their colonic expression and circulating viral load, we were able to 319 narrow further investigations to focus on 3 EREs upregulated in PLWH that might indicate the 320 severity of HIV-1 pathogenesis in the gut, or function as markers of immune deregulation. The 321 EREs LTR19\_12p13.31 and L1FLnI\_1q23.1s best correlated with cellular abundances including



345 responsible for the overexpression of differentially expressed EREs. As the cellular composition 346 of the sequenced tissues fluctuates with disease severity, it is unclear whether the phenotype or 347 mere abundance of disproportionate cell types, such as pDCs and CTLs, is responsible for their 348 expression. Future studies that accurately quantify ERE expression from single cell RNA 349 sequencing data that were not available from this cohort would provide further insight into the 350 activation state of these EREs in the GI tract of PLWH. Additionally, due to the poorly defined 351 molecular characteristics and low copy number of LTR19 HERV sequences, exceedingly little is 352 known about their potential roles in health and disease. LTR19 sequences are a member of the HERVFA clade and are estimated to only possess roughly  $\sim$  15 copies in the human genome<sup>65</sup>. 354 In conclusion, this study provides the first correlative link between ERE expression and 355 the deregulations of GALT observed in untreated HIV-1 infection. While EREs can be 356 modulated in context dependent manners by various aspects of HIV-1 infection, their potential 357 roles in systemic immunity in the GI tract have remained undetermined. We also demonstrate 358 that the IFN-I response mediates ERE expression in uninfected gut CD4+ T cells, however this 359 only appears to be responsible for a distinct subset of roughly 7 differentially expressed 360 elements. It is thus unclear if the HIV-1 lifecycle or IFN-I activity on CD4- cell types in the 361 GALT are responsible for changes in ERE activity. We find that LTR19\_12p13.31 and 362 L1FLnI\_1q23.1s are promising markers of HIV-1 pathogenesis in the gut and may possess 363 undetermined roles in determining cellular composition. This study also provides one of the first 364 observations of a differentially expressed LTR19 elements in a human disease, thus emphasizing 365 the importance of their further study.

366

#### 367 **Contributors**

368 ND co-designed the study, co-prepared the first manuscript draft, co-performed data analyses, 369 co-curated code, led statistical analyses, and curated figures. TF co-prepared the first manuscript 370 draft, co-performed data analyses, co-performed statistical analysis, co-curated code, and 371 provided intellectual input critical to analysis. SM co-designed the study, co-prepared the first 372 manuscript draft, co-performed data analyses, and provided intellectual input critical to data 373 interpretation. NL co-performed analyses and co-curated code. KG provided intellectual input 374 critical to hypothesis generation and co-provided data access. KLM provided intellectual input 375 critical to hypothesis generation and co-provided data access. BSB provided intellectual input 376 critical to hypothesis generation and co-provided data access. MLB provided intellectual input 377 critical to hypothesis testing. SMD provided intellectual input critical to hypothesis generation 378 and testing, co-provided data access, and performed immunological analysis of the gut 379 microenvironment. CCW provided intellectual input critical to hypothesis generation and co-380 provided data access. DFN co-designed the study and co-prepared the first manuscript draft. 381 MLS co-designed the study, co-prepared the first manuscript draft, and co-provided data access. 382 All authors contributed to data interpretation, discussion regarding significances, and editing of 383 the manuscript. All authors have read and approved the final manuscript. 384 385 **Declaration of Interests** 

386 All authors have no potential conflicts of interests to disclose.

387

388 **Acknowledgments** 

389 These works are supported by US NIH grants NCI CA260691 (DFN) and NIAID 390 UM1AI164559 (DFN).

# 

# **Data Sharing Statement**



## 414 **References**

- 415 1. Justiz Vaillant, A. A. & Gulick, P. G. HIV Disease Current Practice. in *StatPearls* (StatPearls
- 416 Publishing, 2023).
- 417 2. Boasso, A., Shearer, G. M. & Chougnet, C. Immune dysregulation in human
- 418 immunodeficiency virus infection: know it, fix it, prevent it? *J. Intern. Med.* **265**, 78–96
- 419 (2009).
- 420 3. Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. *Nat. Rev. Dis.*
- 421 *Primer* **1**, 1–22 (2015).
- 422 4. Life expectancy of individuals on combination antiretroviral therapy in high-income
- 423 countries: a collaborative analysis of 14 cohort studies. *Lancet* **372**, 293–299 (2008).
- 424 5. Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. *Immunity* **48**, 872–895 425 (2018).
- 426 6. Veenhuis, R. T. *et al.* Monocyte-derived macrophages contain persistent latent HIV reservoirs. 427 *Nat. Microbiol.* **8**, 833–844 (2023).
- 428 7. Thompson, C. G., Gay, C. L. & Kashuba, A. D. M. HIV Persistence in Gut-Associated
- 429 Lymphoid Tissues: Pharmacological Challenges and Opportunities. *AIDS Res. Hum.*
- 430 *Retroviruses* **33**, 513–523 (2017).
- 431 8. Kelley, C. F. *et al.* HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1
- 432 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the
- 433 Rectum. *J. Infect. Dis.* **204**, 761–767 (2011).
- 434 9. Mowat, A. McI. & Viney, J. L. The anatomical basis of intestinal immunity. *Immunol. Rev.*
- 435 **156**, 145–166 (1997).



- 437 Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in
- 438 Restoration following Highly Active Antiretroviral Therapy. *J. Virol.* **77**, 11708–11717 (2003).
- 439 11. Dillon, S. M. & Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. *Curr.*
- 440 *HIV/AIDS Rep.* **18**, 128–138 (2021).
- 441 12. Lehmann, C. *et al.* Longitudinal Analysis of Distribution and Function of Plasmacytoid
- 442 Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. *J. Infect. Dis.*
- 443 **209**, 940–949 (2014).
- 444 13. Ansari, A. A. *et al.* Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads
- 445 to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency
- 446 Virus-Infected Rhesus Macaques. *J. Immunol.* **186**, 1044–1059 (2011).
- 447 14. Reeves, R. K. *et al.* SIV Infection Induces Accumulation of Plasmacytoid Dendritic Cells
- 448 in the Gut Mucosa. *J. Infect. Dis.* **206**, 1462–1468 (2012).
- 449 15. Villadangos, J. A. & Young, L. Antigen-Presentation Properties of Plasmacytoid
- 450 Dendritic Cells. *Immunity* **29**, 352–361 (2008).
- 451 16. O'Brien, M., Manches, O. & Bhardwaj, N. Plasmacytoid Dendritic Cells in HIV
- 452 Infection. in *HIV Interactions with Dendritic Cells* (eds. Wu, L. & Schwartz, O.) vol. 762 71–
- 453 107 (Springer New York, 2012).
- 454 17. Guo, K. *et al.* Qualitative Differences Between the IFNα subtypes and IFNβ Influence
- 455 Chronic Mucosal HIV-1 Pathogenesis. *PLoS Pathog.* **16**, e1008986 (2020).
- 456 18. DILLON, S. M. *et al.* A Compartmentalized Type I Interferon Response in the Gut
- 457 During Chronic HIV-1 Infection is Associated with Immunopathogenesis. *AIDS Lond. Engl.*
- 458 **32**, 1599–1611 (2018).

- 459 19. Lander, E. S. *et al.* Initial sequencing and analysis of the human genome. *Nature* **409**, 460 860–921 (2001).
- 461 20. Bourque, G. *et al.* Ten things you should know about transposable elements. *Genome*  462 *Biol.* **19**, 199 (2018).
- 463 21. Bhardwaj, N., Maldarelli, F., Mellors, J. & Coffin, J. M. HIV-1 Infection Leads to
- 464 Increased Transcription of Human Endogenous Retrovirus HERV-K (HML-2) Proviruses *In*
- 465 *Vivo* but Not to Increased Virion Production. *J. Virol.* **88**, 11108–11120 (2014).
- 466 22. Contreras-Galindo, R., López, P., Vélez, R. & Yamamura, Y. HIV-1 infection increases
- 467 the expression of human endogenous retroviruses type K (HERV-K) in vitro. *AIDS Res. Hum.*
- 468 *Retroviruses* **23**, 116–122 (2007).
- 469 23. Vincendeau, M. *et al.* Modulation of human endogenous retrovirus (HERV) transcription 470 during persistent and de novo HIV-1 infection. *Retrovirology* **12**, 27 (2015).
- 471 24. Srinivasachar Badarinarayan, S. *et al.* HIV-1 infection activates endogenous retroviral
- 472 promoters regulating antiviral gene expression. *Nucleic Acids Res.* **48**, 10890–10908 (2020).
- 473 25. Jones, R. B. *et al.* HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary
- 474 isolates. *J. Clin. Invest.* **122**, 4473–4489 (2012).
- 475 26. Contreras-Galindo, R., Almodóvar-Camacho, S., González-Ramírez, S., Lorenzo, E. &
- 476 Yamamura, Y. *Short Communication:* Comparative Longitudinal Studies of HERV-K and
- 477 HIV-1 RNA Titers in HIV-1-Infected Patients Receiving Successful versus Unsuccessful
- 478 Highly Active Antiretroviral Therapy. *AIDS Res. Hum. Retroviruses* **23**, 1083–1086 (2007).
- 479 27. Gonzalez-Hernandez, M. J. *et al.* Expression of Human Endogenous Retrovirus Type K
- 480 (HML-2) Is Activated by the Tat Protein of HIV-1. *J. Virol.* **86**, 7790–7805 (2012).

- 481 28. Contreras-Galindo, R. *et al.* HIV infection reveals widespread expansion of novel
- 482 centromeric human endogenous retroviruses. *Genome Res.* **23**, 1505–1513 (2013).
- 483 29. Jones, R. B. *et al.* LINE-1 retrotransposable element DNA accumulates in HIV-1-infected
- 484 cells. *J. Virol.* **87**, 13307–13320 (2013).
- 485 30. Jones, R. B. *et al.* HIV-1 infection induces retrotransposition of LINE-1 elements.
- 486 *Retrovirology* **6**, P43, 1742-4690-6-S2-P43 (2009).
- 487 31. O'Carroll, I. P. *et al.* Structural Mimicry Drives HIV-1 Rev-Mediated HERV-K
- 488 Expression. *J. Mol. Biol.* **432**, 166711 (2020).
- 489 32. van der Kuyl, A. C. HIV infection and HERV expression: a review. *Retrovirology* **9**, 6
- 490 (2012).
- 491 33. Kyriakou, E. & Magiorkinis, G. Interplay between endogenous and exogenous human 492 retroviruses. *Trends Microbiol.* **31**, 933–946 (2023).
- 493 34. Brinzevich, D. *et al.* HIV-1 Interacts with Human Endogenous Retrovirus K (HML-2)
- 494 Envelopes Derived from Human Primary Lymphocytes. *J. Virol.* **88**, 6213–6223 (2014).
- 495 35. An, D. S., Xie, Y. & Chen, I. S. Y. Envelope Gene of the Human Endogenous Retrovirus
- 496 HERV-W Encodes a Functional Retrovirus Envelope. *J. Virol.* **75**, 3488–3489 (2001).
- 497 36. Ogata, T., Okui, N., Sakuma, R., Kobayashi, N. & Kitamura, Y. Integrase of human
- 498 endogenous retrovirus K-10 supports the replication of replication-incompetent Int- human
- 499 immunodeficiency virus type 1 mutant. *Jpn. J. Infect. Dis.* **52**, 251–252 (1999).
- 500 37. Monde, K., Contreras-Galindo, R., Kaplan, M. H., Markovitz, D. M. & Ono, A. Human
- 501 Endogenous Retrovirus K Gag Coassembles with HIV-1 Gag and Reduces the Release
- 502 Efficiency and Infectivity of HIV-1. *J. Virol.* **86**, 11194–11208 (2012).

- 503 38. Terry, S. N. *et al.* Expression of HERV-K108 envelope interferes with HIV-1 production.
- 504 *Virology* **509**, 52–59 (2017).
- 505 39. Fueyo, R., Judd, J., Feschotte, C. & Wysocka, J. Roles of transposable elements in the
- 506 regulation of mammalian transcription. *Nat. Rev. Mol. Cell Biol.* **23**, 481–497 (2022).
- 507 40. Du, A. Y., Chobirko, J. D., Zhuo, X., Feschotte, C. & Wang, T. *Regulatory Transposable*
- 508 *Elements in the Encyclopedia of DNA Elements*.
- 509 http://biorxiv.org/lookup/doi/10.1101/2023.09.05.556380 (2023)
- 510 doi:10.1101/2023.09.05.556380.
- 511 41. Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity
- 512 through co-option of endogenous retroviruses. *Science* **351**, 1083–1087 (2016).
- 513 42. Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the 514 bad with the good. *Nat. Rev. Immunol.* **16**, 207–219 (2016).
- 515 43. Payer, L. M. & Burns, K. H. Transposable elements in human genetic disease. *Nat. Rev.*  516 *Genet.* **20**, 760–772 (2019).
- 517 44. Küry, P. *et al.* Human Endogenous Retroviruses in Neurological Diseases. *Trends Mol.*  518 *Med.* **24**, 379–394 (2018).
- 519 45. Jansz, N. & Faulkner, G. J. Endogenous retroviruses in the origins and treatment of 520 cancer. *Genome Biol.* **22**, 147 (2021).
- 521 46. Dopkins, N. & Nixon, D. F. Activation of human endogenous retroviruses and its
- 522 physiological consequences. *Nat. Rev. Mol. Cell Biol.* (2023) doi:10.1038/s41580-023-00674- 523 z.
- 524 47. De Mulder, M. *et al.* Anti-HERV-K (HML-2) capsid antibody responses in HIV elite
- 525 controllers. *Retrovirology* **14**, 41 (2017).

- 526 48. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 527 (2013).
- 528 49. Bendall, M. L. *et al.* Telescope: Characterization of the retrotranscriptome by accurate
- 529 estimation of transposable element expression. *PLoS Comput. Biol.* **15**, e1006453 (2019).
- 530 50. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
- 531 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 532 51. Gao, C.-H., Yu, G. & Cai, P. ggVennDiagram: An Intuitive, Easy-to-Use, and Highly
- 533 Customizable R Package to Generate Venn Diagram. *Front. Genet.* **12**, 706907 (2021).
- 534 52. Ito, K. & Murphy, D. Application of ggplot2 to Pharmacometric Graphics. *CPT*
- 535 *Pharmacomet. Syst. Pharmacol.* **2**, e79 (2013).
- 536 53. Dillon, S. M. *et al.* An altered intestinal mucosal microbiome in HIV-1 infection is
- 537 associated with mucosal and systemic immune activation and endotoxemia. *Mucosal*
- 538 *Immunol.* **7**, 983–994 (2014).
- 539 54. Dillon, S. M. *et al.* Gut dendritic cell activation links an altered colonic microbiome to
- 540 mucosal and systemic T-cell activation in untreated HIV-1 infection. *Mucosal Immunol.* **9**, 24– 541 37 (2016).
- 542 55. O'Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status,
- 543 taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **44**, D733–D745 (2016).
- 544 56. Harrow, J. *et al.* GENCODE: the reference human genome annotation for The ENCODE 545 Project. *Genome Res.* **22**, 1760–1774 (2012).
- 546 57. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV):
- 547 high-performance genomics data visualization and exploration. *Brief. Bioinform.* **14**, 178–192 548 (2013).

- 549 58. Pertea, M. *et al.* StringTie enables improved reconstruction of a transcriptome from
- 550 RNA-seq reads. *Nat. Biotechnol.* **33**, 290–295 (2015).
- 551 59. Jones, S. T. *et al.* Altered Immunoglobulin Repertoire and Decreased IgA Somatic
- 552 Hypermutation in the Gut during Chronic HIV-1 Infection. *J. Virol.* **96**, e0097622 (2022).
- 553 60. Dillon, S. M. *et al.* Granzyme B+ CD4 T cells accumulate in the colon during chronic
- 554 HIV-1 infection. *Gut Microbes* **14**, 2045852 (2022).
- 555 61. Kassiotis, G. The Immunological Conundrum of Endogenous Retroelements. *Annu. Rev.*  556 *Immunol.* **41**, annurev-immunol-101721-033341 (2023).
- 557 62. Curty, G. *et al.* Human Endogenous Retrovirus Expression Is Upregulated in the Breast
- 558 Cancer Microenvironment of HIV Infected Women: A Pilot Study. *Front. Oncol.* **10**, 553983 559 (2020).
- 560 63. Dai, L. *et al.* Transactivation of human endogenous retrovirus K (HERV-K) by KSHV

561 promotes Kaposi's sarcoma development. *Oncogene* **37**, 4534–4545 (2018).

- 562 64. Macchietto, M. G., Langlois, R. A. & Shen, S. S. Virus-induced transposable element
- 563 expression up-regulation in human and mouse host cells. *Life Sci. Alliance* **3**, e201900536 564 (2020).
- 565 65. Vargiu, L. *et al.* Classification and characterization of human endogenous retroviruses; 566 mosaic forms are common. *Retrovirology* **13**, 7 (2016).
- 567
- 568
- 569
- 570
- 571

## 572 **Figure Legends**

573

## 574 **Figure 1. HIV-1 status influences endogenous retroelement expression in the gut**

#### 575 **microenvironment**

- 576 Heatmap demonstrating the normalized per sample abundances of EREs following the
- 577 preprocessing filtering of reads in uninfected controls (red)  $(n = 13)$  vs PLWH (blue)  $(n = 19)$
- 578 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for
- 579 quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs
- 580 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq$ -1 between
- 581 uninfected controls (red)  $(n = 13)$  and PLWH (blue)  $(n = 19)$  gut biopsies. All statistics were
- 582 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default
- 583 parameters for a Benjamini-Hochberg correction (B). Volcano plot demonstrating the average
- 584 fold change  $\geq 1$  or  $\leq$ -1 and an adjusted p value of  $\leq$ 0.05 and a LFC between uninfected controls (n
- 585 = 13) and PLWH ( $n = 19$ ) gut biopsies. All statistics were performed in DESEQ using the Wald's
- 586 Test. Adjusted p values were calculated using default parameters for a Benjamini-Hochberg

587 correction (C).

588

# 589 **Figure 2. Correlation between gut endogenous retroelement expression and viral load in**  590 **people living with HIV-1**

591 Scatterplot demonstrating the viral load from serum on the X axis and normalized expression of

- 592 L1FLnI\_1q23.1s in colon biopsies on the Y axis. uninfected controls (red)  $(n = 13)$  vs PLWH
- 593 (blue)  $(n = 19)$  (A). Normalized expression of L1FLnI\_1q23.1s in colon biopsies from
- 594 uninfected controls (red)  $(n = 13)$  vs PLWH (blue)  $(n = 19)$ . Post hoc significance values



618 biopsies on the Y axis. uninfected controls (red)  $(n = 13)$  vs PLWH (blue)  $(n = 19)$  (K).

619 Normalized expression of LTR19 12p13.31 in colon biopsies from uninfected controls (red) (n =

620 13) vs PLWH (blue) ( $n = 19$ ). Post hoc significance values determined with unpaired T test (L).

621 Normalized expression of LTR19  $12p13.31$  in PBMCs from uninfected controls (red) (n = 13)

622 vs PLWH (blue) ( $n = 19$ ). Post hoc significance values determined with unpaired T test (M).

623 Interferome array of L1FLnI\_1q23.1s expression following IFN-a1 (n = 3), -a2 (n = 3), -a5 (n =

624 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+ T cells when compared to mock (m)

625 treatment (n=3). ANOVA performed for significance with post hoc significance values

626 determined via unpaired T test (N). IGV representation of LTR19\_12p13.31 locus provided by

627 the Telescope annotation in the Refseq and Gencode annotations. StringTie reconstructed

628 transcriptomes demonstrate putative transcripts present in sequencing collected from the colon of

629 uninfected controls and PLWH individuals (O).

630

#### 631 **Figure 3. Correlation Between LTR19\_12p13.31 and L1FLnI\_1q23.1s expression and**

#### 632 **immune signatures of the gut microenvironment in people living with HIV-1.**

633 For all samples uninfected controls (red)  $(n = 13)$  vs PLWH (blue)  $(n = 19)$ . Scatterplot

634 demonstrating the CD4+ T Cells per gram on the X axis and normalized expression of

635 LTR19 12p13.31 in colon biopsies on the Y axis (A). Scatterplot demonstrating the CD4+ T

636 Cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on

637 the Y axis (B). Scatterplot demonstrating the CD8+ T Cells per gram on the X axis and

638 normalized expression of LTR19\_12p13.31 in colon biopsies on the Y axis (C). Scatterplot

639 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of

640 L1FLnI  $1q23.1s$  in colon biopsies on the Y axis (D). Scatterplot demonstrating the IFNy+CD8+



# 664 **Supplemental Legends**

665



682

# 683 **Figure S2: Characterization of ERE expression profiles in uninfected gut CD4+ T cells**

684 **activated with IFN-Is**. PCA plot based solely on ERE abundances demonstrate variance in

685 sample distribution between mock (m) (n=3), IFN $\alpha$ 1 (a1) (n = 3), IFN $\alpha$ 2 (a2) (n = 3), IFN $\alpha$ 5 (a5)

686 (n = 3), IFN $\alpha$ 8 (a8) (n = 3), IFN $\alpha$ 14 (a14) (n = 3), and IFN $\beta$  (b) (n = 3) treated gut CD4+ T cells

687 (A). Stacked bar charts demonstrating mean abundance of exonic, intronic, and intergenic TEs as 688 the average proportion of ERE denoted reads from m  $(n=3)$ , a1  $(n=3)$ , a2  $(n=3)$ , a5  $(n=3)$ , a8 689 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells (B). Stacked bar charts demonstrating 690 mean abundance of LINE1 and HERV elements as the average proportion of ERE denoted reads 691 from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut 692 CD4+ T cells (C). Stacked bar charts demonstrating the chromosomal location of ERE denoted 693 reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated 694 gut CD4+ T cells (D). Stacked bar charts demonstrating ERE category as the average proportion 695 of TE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and 696 b (n = 3) treated gut CD4+ T cells (E). Stacked bar charts demonstrating mean abundance of TE 697 families as the average proportion of TE denoted reads from m  $(n=3)$ , a1  $(n=3)$ , a2  $(n=3)$ , a5  $(n=3)$ 698 = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells (F).

699

# 700 **Figure S3: IFN-Is induce the differential expression of EREs in gut CD4+ T cells**. Heatmap 701 demonstrating the normalized per sample abundances of TEs following the preprocessing 702 filtering of reads in m (gold) (n=3), a1 (purple) (n = 3), a2 (pink) (n = 3), a5 (green) (n = 3), a8 703 (blue) (n = 3), a14 (red) (n = 3), and b (teal) (n = 3) treated gut CD4+ T Cells. ERE reads were 704 filtered to possess at least 2 reads in 10% of the total samples for quality assurance (A). 705 Heatmap demonstrating the normalized per sample abundances of EREs differentially expressed 706 with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq$ -1 between m (red) (n=3) and a1 (blue) 707 (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ using the Wald's Test. 708 Adjusted p values were calculated using default parameters for a Benjamini-Hochberg correction 709 (B). Heatmap demonstrating the normalized per sample abundances of EREs differentially



732 uniquely upregulated ERE loci across a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3),

733 and b  $(n = 3)$  treated gut CD4+ T cells when compared to m (I).

734

# 735 **Figure S4: Upregulation of ERE loci in gut CD4+ T cells activated with IFN-Is**. Volcano plot 736 demonstrating the average fold change  $\geq$ 1 or  $\leq$ -1 and an adjusted p value of  $\leq$ 0.05 and a LFC 737 between m  $(n = 3)$  and a1  $(n = 3)$  treated gut CD4+ T cells. All statistics were performed in 738 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 739 Benjamini-Hochberg correction (A). Volcano plot demonstrating the average fold change ≥1 or≤- 740 1 and an adjusted p value of ≤0.05 and a LFC between m (n = 3) and a2 (n = 3) treated gut CD4+ 741 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were 742 calculated using default parameters for a Benjamini-Hochberg correction (B). Volcano plot 743 demonstrating the average fold change  $\geq 1$  or  $\leq$ -1 and an adjusted p value of  $\leq$ 0.05 and a LFC 744 between m  $(n = 3)$  and a5  $(n = 3)$  treated gut CD4+ T cells. All statistics were performed in 745 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 746 Benjamini-Hochberg correction (C). Volcano plot demonstrating the average fold change ≥1 or≤- 747 1 and an adjusted p value of  $\leq 0.05$  and a LFC between m (n = 3) and a8 (n = 3) treated gut CD4+ 748 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were 749 calculated using default parameters for a Benjamini-Hochberg correction (D). Volcano plot 750 demonstrating the average fold change  $\geq$ 1 or  $\leq$ -1 and an adjusted p value of  $\leq$ 0.05 and a LFC 751 between m  $(n = 3)$  and a14  $(n = 3)$  treated gut CD4+ T cells. All statistics were performed in 752 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a 753 Benjamini-Hochberg correction (E). Volcano plot demonstrating the average fold change ≥1 or≤- 754 1 and an adjusted p value of  $\leq 0.05$  and a LFC between m (n = 3) and b (n = 3) treated gut CD4+

755 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were

- 756 calculated using default parameters for a Benjamini-Hochberg correction (F).
- 757

## 758 **Figure S5: HIV-1 status and IFN-Is induce 7 shared EREs in the gut microenvironment**.

- 759 Venn diagram of shared vs uniquely downregulated TE loci across PLWH (n = 19) vs uninfected
- 760 controls (n = 13) gut biopsies, and a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b
- 761 (n = 3) treated gut CD4+ T cells when compared to m (A). Venn diagram of shared vs uniquely
- 762 upregulated TE loci across PLWH ( $n = 19$ ) vs uninfected controls ( $n = 13$ ) gut biopsies, and a1 (n
- 763 = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells when
- 764 compared to m (B). Gut biopsies from uninfected controls ( $n = 13$ ) and PLWH ( $n = 19$ )
- 765 individuals (left) as well interferome assay responses to type 1 interferons ( $n = 3$ ) (right) show
- 766 significant upregulation in HARLEQUIN\_17q12 (C), HERV4\_4q22.1 (D), MER101\_2p25.2 (E),
- 767 MER4\_7q21.2 (F), L1FLnI\_1p22.2l (G), L1FLnI\_9p21.1ha (H), and L1FLnI\_17q12k (I). All
- 768 statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated
- 769 using default parameters for a Benjamini-Hochberg correction. Tukey box and whisker plots for
- 770 with the line demonstrating the median of expression while the large dot represents the mean.
- 771

#### 772 **Figure S6: EREs of interest in the gut microenvironment show no association with CD1c+**

- 773 **mDC abundances**. Gut expression of L1FLnI\_1q23.1s (A), L1FLnI\_5q32o (B), and
- 774 LTR19\_12p13.31 (C) show no association with CD1c+ mDC abundances in the gut
- 

775 microenvironment.



- 778 **deregulation in PLWH**. Scatterplot demonstrating the CD4+ T Cells per gram on the X axis and
- 779 normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (A). Scatterplot
- 780 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of
- 781 L1FLnI\_5q32o in colon biopsies on the Y axis (B). Scatterplot demonstrating the IFNy+CD8+ T
- 782 Cells per gram on the X axis and normalized expression of L1FLnI\_5q32o in colon biopsies on
- 783 the Y axis (C). Scatterplot demonstrating the CD11c+ mDCs per gram on the X axis and
- 784 normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (D). Scatterplot
- 785 demonstrating the pDCs per gram on the X axis and normalized expression of L1FLnI\_5q32o in
- 786 colon biopsies on the Y axis (E). Scatterplot demonstrating the CD1c- mDCs per gram on the X

787 axis and normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (F).

788

#### 789 **Figure S8: Association between colonic L1FLnI\_1q23.1s expression and CD4+ T Cell**

790 **subsets**. Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and

791 normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y axis (A). Scatterplot

792 demonstrating the IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression

793 of L1FLnI\_1q23.1s in colon biopsies on the Y axis (B). Scatterplot demonstrating the

794 IFNy+IL17+CD4+ T cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s

795 in colon biopsies on the Y axis (C). Scatterplot demonstrating the IL22+IFNy-IL17-CD4+ T cells

796 per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y

797 axis (D).



# 818 **Figure S11: Colonic expression of EREs of interest produce negligible correlations with**

- 819 **serum IL-6 and LPS**. Scatterplots demonstrating serum lipopolysaccharide (LPS)
- 820 concentrations on the X axis and normalized expression of L1FLnI\_1q23.1s (A), L1FLnI\_5q32o
- 821 (B), LTR19\_12p13.31 (C) in colon biopsies on the Y axis. Scatterplots demonstrating serum IL-6

- 822 concentrations on the X axis and normalized expression of L1FLnI\_1q23.1s (D), L1FLnI\_5q32o 823 (E), LTR19  $12p13.31$  (F) in colon biopsies on the Y axis.
- 824

#### 825 **Figure S12: HIV-1 status influences endogenous retroelement expression in the PBMC**

- 826 **fraction.** Heatmap demonstrating the normalized per sample abundances of EREs following the
- 827 preprocessing filtering of reads in uninfected controls (red)  $(n = 13)$  vs PLWH (blue)  $(n = 19)$
- 828 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for
- 829 quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs
- 830 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq$ -1 between
- 831 uninfected controls (red)  $(n = 13)$  and PLWH (blue)  $(n = 19)$  gut biopsies. All statistics were
- 832 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default
- 833 parameters for a Benjamini-Hochberg correction (B). PCA plot based solely on ERE abundances
- 834 demonstrate no variance in sample distribution between uninfected controls (red)  $(n = 13)$  and
- 835 PLWH (blue)  $(n = 19)$  PBMCs (C).
- 836
- 837
- 838
- 839
- 840
- 841
- 842
- 843
- 844

# 845 **Supplemental Table**

#### 846



Plasma *HIV RNA copies/ml*





869

870 *Evidence before this study* 

- 872 Previous studies have demonstrated that HIV-1 infection alters the physiology of the GI tissues, 873 where it forms quiescent reservoirs. In chronic HIV-1, the sustainment of antiviral immune 874 responses through poorly understood mechanisms likely contributes to pathogenesis and 875 prohibits effective clearance of the viral reservoirs. EREs comprise a substantial portion of the 876 human genome that has been implicated in HIV-1 pathogenesis but remains understudied in 877 comparison to coding genes. Therefore, studying the activity of EREs in tissues such as the GI 878 tract may help further define the physiology of immunopathologies that contribute to HIV-1 879 reservoir persistence. 880 881 *Added value of this study*  882 883 Colon pinch biopsies from PLWH demonstrate differential expression of 59 EREs when 884 compared to uninfected controls. Of these 59, 3 possess near-significant correlations with viral 885 load. Further analysis into cellular composition of the gut microenvironment demonstrates that 2 886 the EREs LTR19\_12p13.31 and L1FLnI\_1q23.1s possess significant associations with immune 887 cell phenotypes indicative of localized HIV-1 pathogenesis. Therefore, high expression of 888 LTR19\_12p13.31 and L1FLnI\_1q23.1s can function as markers of GI HIV-1 reservoirs, as well 889 as potentially possess undefined roles in human health.
- 890

# 891 *Implications of all the available evidence*

- 893 Recurrent observations suggest pathophysiological roles for differentially expressed EREs in
- 894 diseased tissues. In HIV-1 infection, EREs can be over expressed due to trans-activation of
- 895 HERV LTRs and shifts in the regulome that permit the expression of typically silent elements.
- 896 However, it has not been established how EREs may be deregulated in the gut where
- 897 immunopathologies persist surrounding viral reservoirs. Correlations between ERE expression
- 898 and cellular composition demonstrate that certain EREs may be indicative of cell type
- 899 abundances thought to drive GI-specific immunopathologies resultant from HIV-1 infection.

#### **Controls vs PLWH Gut Biopsies**









total =  $13706$  variables



